Nirmatrelvir/ritonavir (NMV/r) is used for the treatment of coronavirus disease 2019 (COVID-19) infection. However, rebound COVID-19 infections can occur after taking NMV/r. We examined neutralizing antibodies to the severe acute respiratory syndrome coronavirus 2 spike protein before and after infection in people who did and did not take NMV/r to determine if NMV/r impedes the humoral immune response.
Association of Nirmatrelvir/Ritonavir Treatment and COVID-19-Neutralizing Antibody Titers in a Longitudinal Health Care Worker Cohort.
纵向医护人员队列中尼马替韦/利托那韦治疗与 COVID-19 中和抗体滴度的关联
阅读:14
作者:Decker Slade, Xiao Shaoming, Dillen Carly, Schumacher Christina M, Milstone Aaron M, Frieman Matthew, Debes Amanda K
| 期刊: | Open Forum Infectious Diseases | 影响因子: | 3.800 |
| 时间: | 2024 | 起止号: | 2024 Feb 13; 11(2):ofad625 |
| doi: | 10.1093/ofid/ofad625 | 研究方向: | 免疫/内分泌 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
